Several brokerages have updated their recommendations and price targets on shares of Oncocyte (NASDAQ: IMDX) in the last few weeks:
- 12/4/2025 – Oncocyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/28/2025 – Oncocyte had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/22/2025 – Oncocyte was upgraded by analysts at Wall Street Zen to a “hold” rating.
- 11/21/2025 – Oncocyte is now covered by analysts at Weiss Ratings. They set a “sell (d-)” rating on the stock.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.
See Also
- Five stocks we like better than Oncocyte
- What is a Microcap Stock? Everything You Need to Know
- Tesla Bulls See $500 Ahead—But Bears Warn of a Painful Reversal
- What is MarketRank™? How to Use it
- Missed NVIDIA? Braze Might Be the Next AI Stock Breakout
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Walmart’s NASDAQ Switch Could Change Everything for WMT Stock
Receive News & Ratings for Oncocyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte Corp and related companies with MarketBeat.com's FREE daily email newsletter.
